HC Wainwright Predicts Reduced Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Research analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Krystal Biotech in a research report issued to clients and investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $1.71 per share for the quarter, down from their previous forecast of $1.74. HC Wainwright has a "Buy" rating and a $240.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's Q3 2025 earnings at $1.94 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%.

Other research analysts also recently issued reports about the company. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Citigroup boosted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday. Finally, Guggenheim cut their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $218.63.

Krystal Biotech Stock Performance

Krystal Biotech stock traded down $4.94 during trading hours on Thursday, hitting $132.23. 329,798 shares of the stock were exchanged, compared to its average volume of 300,407. The stock has a market capitalization of $3.82 billion, a P/E ratio of 44.22 and a beta of 0.79. The business's 50-day moving average is $171.56 and its two-hundred day moving average is $170.04. Krystal Biotech has a 12 month low of $131.71 and a 12 month high of $219.34.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Institutional Trading of Krystal Biotech

Hedge funds have recently added to or reduced their stakes in the business. FMR LLC increased its holdings in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after acquiring an additional 21,133 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC increased its stake in Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after purchasing an additional 6,600 shares in the last quarter. Hood River Capital Management LLC raised its holdings in Krystal Biotech by 2.1% during the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after buying an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).